Radient Pharmaceuticals Provides Domestic and International Target Market Details for Its Onko-Sure(R) IVD Cancer ...

26 August 2010, 5:59 am

TUSTIN, CA--(Marketwire - 08/26/10) - Radient Pharmaceuticals Corporation (RPC) (AMEX: RPC - News ) announced today target market details for the domestic and international commercialization of its Onko-Sure in vitro diagnostic (IVD) cancer test. RPC received USFDA for its Onko-Sure IVD cancer test approximately 24 months ago, which marked the point at which RPC could begin commercialization ...... Read More »

More Topics from "News"

• Vita-Tech International Donates Nutritional Products in Africa
• Company Profile for MDLsolutions, Inc.
• Advanced Feeedback Systems Translate to Lower Costs for Fluid Research Meter, Mix, Dispense ...
• NAFA PSW Chapter to Hold Golf Outing in October
• Peregrine to Report First Quarter Fiscal Year 2011 Financial Results After Market on September 9, 2010
• First day of school for Tustin Unified
• Radient Pharmaceuticals Resumes Collaboration to Advance Its Onko-Sure(R) In Vitro Diagnostic Cancer Test in the USA
• 628-Unit Creekside Meadows Apartments Trades